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Abstract 
Mass spectrometry imaging (MSI) is increasingly being used as a label free method of 
evaluating the distribution of drugs and endogenous compounds in tissues. The technology 
has been welcomed by drug researchers eager to perform drug distribution studies at an earlier 
stage in the discovery timeline. The technology however is not limited to drug distribution 
studies but can also be used to detect a wide range of chemical species rendering it applicable 
to both pharmacokinetic and pharmacodynamic endpoints. Traditionally MSI has been used in 
a qualitative capacity, however it is increasingly being used for quantitative assessments of 
drug levels in tissue sections. 
Here we report quantitative mass spectrometry imaging (qMSI) methodology for the analysis 
of endogenous amino acids (lactate and glutamate) in mouse tumor models. We describe pre-
analysis stabilization methods aimed at improving quantitative assessment of endogenous 
small molecules. Additionally, we apply qMSI methodology to monitor lactate modulation in 
tumors after dosing animals with a proprietary drug (AZx) known to effect energy metabolism 
in cancer cells. Finally, we use regio-specific qMSI to identify a tumor model that has low 
lactate heterogeneity in an effort to decrease inter tumor variability and enable accurate 
measurement of lactate modulation in pre-clinical efficacy studies. 
 
Introduction 
Oncology is a growing research area in pharmaceutical R&D.  The complex nature of cancer 
has prompted research into many potentially therapeutic pathways targeting changes in cancer 
cell growth, division, proliforation and death, making the space highly competitive and 
congested. In the search for ever more novel approaches in the fight against cancer 
researchers have now begun to focus on ways to make the body’s own immune system 
specifically target cancer cells, an area known as immuno-oncology. 
A common difference between tumor cells and normally differentiated cells is a change in 
cellular metabolism. Otto Warburg documented the classic metabolic shift of cancer cells to 
aerobic glycolysis, higher energy production and increased lactate concentration
1
. More 
recently Vander Heiden et al. have hypothesized that adaptations to the metabolic pathways in 
tumor cells are an aide to cellular proliferation, facilitating uptake and incorporation of 
nutrients into the constituents needed for the generation of new cells
2
. The list of pathways 
affected by cellular disease state is wide and varied and as such has become the focus of 
pharmaceutical companies wishing to find new pharmacological targets and ultimately 
improve the living standards of cancer patients. 
Metabolic features of the Warburg effect are a hallmark of cancer, where most tumors rely on 
glucose and glutamine catabolism to produce ATP and the building blocks necessary to 
sustain rapid cell growth
3
. The balance of nutrients and oxygen within the tumor 
microenvironment controls immune cell function. Glucose and amino acid consumption by 
tumor cells can outpace that of infiltrating immune cells, specifically depriving them of 
nutrients to fuel their effector function. Poorly perfused tumor regions drive hypoxia response 
programs in tumor cells, macrophages, and T cells. Increased HIF-1a activity in response to 
hypoxia or other mechanisms promotes glycolysis and increases concentrations of suppressive 
metabolites and acidification of the local environment. As a by-product of glycolysis, lactate 
concentration increases, which is co-ordinately utilized by tumor cells to fuel their 
metabolism, promote macrophage polarization, and directly suppresses T cell function
4
. 
Kreutz and colleagues (Brand et al., 2016) reported a novel mechanism whereby lactic acid 
produced by highly glycolytic tumors overcomes immune surveillance, by impairing 
activation of infiltrating cytotoxic CD8+ T and NK cells
5
. 
Developing therapeutic approaches to modify T cells to utilize lactate as an energy and 
biomolecule source, similar to the pathways operating in some tumor cells, or reducing the 
levels of lactate in the micro-environment may provide means to overcome this hurdle for 
tumor immunity.  
Analytical methodologies that enable quantitative evaluation of tumor lactate levels in the 
tumor microenvironment are critical when developing potential new treatments. Furthermore, 
given the complex and heterogenic tumor architecture, spatial information of tumor lactate 
levels can provide valuable information to better understand both the endogenous distribution 
of tumor lactate and also the effects on endogenous levels after drug dosing in animal model 
efficacy testing. This understanding can then enable reliable pharmacokinetic-
pharmacodynamic (PK-PD) understanding of the modulation of tumor lactate levels and how 
they correlate with overall effects on tumor growth. 
Drug discovery is a lengthy, costly and competitive business. Potential new drugs can take 
more than ten years to reach commercialization, at a cost of billions of dollars. Furthermore, 
attrition rates during the later stages of development increase the already high risk factors 
involved with taking a new compound into the clinic
6
. Pharmaceutical companies have gone 
to great lengths to decrease these high failure rates, minimising risk in an effort to maximize 
reward and bring new medicines to the market
7
. Poor efficacy and toxicity are the main 
reasons for high attrition rates within research and development (R&D)
8
. The industry has 
addressed this problem by adopting a strategy of early, accelerated compound optimisation 
with parallel generation of physicochemical and pharmacokinetic properties to design safer 
and more efficacious drug candidates that maximize therapeutic index whilst minimising any 
risk of toxicity
9
. 
Bioanalytical techniques such as LC-MS have kept pace with the need for higher throughput
10
 
but are limited in value when trying to assess a drug’s distribution in vivo. Traditionally drug 
distribution studies were performed during the later stages of development using radiolabelled 
compounds in low throughput techniques such as qWBA
11
 or homogenization
12
 studies using 
LC-MS with long liquid chromatography gradients. Mass spectrometry imaging (MSI) is a 
term given to a group of label free, multiplex analytical techniques that can essentially map 
the molecular distribution of endogenous compounds, drugs
13
, lipids
14
, proteins
15
, peptides
16
 
and drug delivery systems
17
 in biological tissues. MSI techniques are all based on different 
mass spectrometry surface sampling ion sources of which matrix assisted laser desorption 
ionization mass spectrometry imaging (MALDI-MSI)
18
 has  arguably the most widespread 
use within the pharmaceutical industry. MALDI-MSI is being rapidly joined by other MSI 
techniques such as desorption electrospray ionization mass spectrometry imaging (DESI-
MSI)
19
 and liquid extraction surface analysis mass spectrometry imaging (LESA-MSI)
20
 that 
bring complementary properties such as an expanded chemical scope and increased 
sensitivity, usually at the expense of decreased spatial resolution. Essentially, each technique 
rasters or continuously scans across tissue sections acquiring a constant full mass spectrum at 
each pixel or coordinate, each mass signal within the spectrum is assigned an intensity that 
can then be color coded into a heat map image describing the relative abundance of an analyte 
within the tissue. 
Whilst not replacing traditional bioanalysis, MSI is increasingly being used alongside these 
techniques providing timely and cost effective insights into the deposition and fate of new 
chemical entities
21
. The application of the technique has been expanded further to encompass 
endogenous compound changes as markers for drug induced efficacy
22
 or toxicity
23
. 
Applications of MSI within the drug discovery industry are well documented
24
. It has 
increasingly been used to provide molecular distribution information at an early stage of the 
drug development pipeline. Several groups have reported successful imaging of low mass 
endogenous metabolites in tumors
25
. Data has largely been qualitative in nature but in order to 
expand the applicability of MALDI-MSI into pharmacodynamic testing of compound 
efficacy, quantitative mass spectrometry imaging (qMSI) methods are needed that can 
spatially resolve regions of high abundance in what is often complex tumor architecture. 
Here we present a mass spectrometry imaging methodology for the absolute quantitation of 
two key endogenous metabolites involved in tumor cell energy production (glycolysis and the 
TCA cycle), lactate and glutamate. The techniques developed were used to screen several 
mouse tumor models to identify a suitable phenotype to reliably monitor lactate changes post 
drug administration in efficacy studies. We also present regiospecific quantitation post 
spectral segmentation to highlight the heterogeneity of each tumor model. 
 
Methods 
Materials and reagents 
Analytical grade acetonitrile, methanol and formic acid were obtained from Fisher Scientific 
(Loughborough, Leicestershire, UK). 2-methylbutane, gelatin, lactate-
13
C3, lactate 
13
C1, 
Glutamate-D3,
 
 1, 5-diaminonaphthalene and 9-aminoacridine were purchased from  
Sigma-Aldrich (Poole, Dorset, UK). Test compound for the efficacy study was obtained in-
house from AstraZeneca compound management group (Macclesfield, Cheshire, UK). 
Lactate-
13
C1 and Glutamate-D5 were purchased from QMX Laboratories (Thaxted, Essex, 
UK). 
Amino acid stability in rat kidney sections 
Duplicate control kidney sections (10µm) were cut and mounted onto glass microscope slides 
over a 24h time-course (0, 0.5, 18, 21 & 24h). Sections were stored at one of three different 
conditions between time-points; (1) left in the cryostat thaw mounted at -16ºC, (2) thaw 
mounted, dessicated in N2, vacuum packed and stored at ambient temperature, or (3) thaw 
mounted, dessicated in N2, vacuum packed and stored at -80ºC. A ‘fresh’ kidney section was 
mounted on each slide prior to analysis by desorption electrospray mass spectrometry 
imaging.  
 
Animals studies 
All animal studies were conducted in accordance with UK Home Office legislation, the 
Animal Scientific Procedures Act 1986, and the AstraZeneca Global Bioethics policy. All 
experimental work is outlined in home office license 40/8894, which has gone through the 
AstraZeneca Ethical Review Process. 
 
Initial proof of priciple study (AZx) 
AZx was dosed at 3 dose levels (3, 30 and 100 mg/kg) to athymic nude mice from a NCI-
H358 tumor model over an 8 day period. Five animals from each dose level were sacrificed at 
0.5, 2, 6 and 24 h post dose. Five time-matched vehicle dosed animals at each dose level were 
also euthanized to act as a direct comparison. All tumors were resected at necropsy and snap 
frozen in dry ice chilled 2-methyl butane. The tumors were stored at -80°C prior to cryo-
sectioning and subsequent analysis. 
 
Mouse models (Screening) 
Four different female athymic nude mice tumor models were screened for lactate and 
glutamate concentration and distribution. The four models tested were NCI-H358 (a human 
xenograft model grown in nude mice), MC38, B16.F10.AP3 and a MC38 Variant (all 
syngeneic mouse tumor models) 
 
Tissue Embedding 
Tissue embedding methodology can be found in the supplementary information.  
Sectioning 
Details of the methodology used in cryosectioning the tissues used in this study can be found 
in the supplementary information. 
    
DESI mass spectrometry imaging 
Details of the DESI-MSI method used in the stability experiments can be found in the 
supplementary information. 
 
Lactate calibration standard preparation 
Three stock solutions of Sodium L-lactate-
13
C3 solution (Sigma-Aldrich, 485926-500MG) 
were prepared daily as needed at concentrations of 500, 5000 and 50000 µM in 50/50 v/v 
Methanol/Water. A sample of blank 50/50 v/v methanol/water was also retained. 
 
Calibration spots for quantitation were added to control tissue sections (on each day of 
analysis) using a Preddator robotic liquid handler (Redd and Whyte, London, UK),  at 
amounts equal to 0, 10, 25, 50, 100, 250 and 500 ng of lactate on-tissue. The liquid handler 
dispensed 50 nL droplets of the standards and over spotting in a total of 4 cycles to reach the 
required on-tissue amounts of the analyte. Spots were allowed to dry at room temperature 
prior to matrix addition. 
 
Glutamate calibration standard preparation 
Stock solutions of D3-glutamate and D5-glutamate were prepared daily at 100 mM in 0.1 M 
HCl. D5-glutamate standards were prepared by dilution in 50 % EtOH to concentrations of 2 
mM, 0.67 mm, 0.22 mM, 0.074 mM, and 0.025 mM. 0.1 µl of the standards and a blank 
sample (50% EtOH) were manually applied to control tissue. D5-glutamate was used as an 
internal standard. 50 µl of the stock solution was added to 5.95 ml of 50% MeOH and sprayed 
onto the tissue before matrix application application using a TM-sprayer (HTX technologies, 
Chapel Hill, NC, USA) with the following parameters; 6 passes at 90°C using a flow 50% 
methanol/water v/v at a flow rate of 0.07 mL/min and nebulized with nitrogen at 6 psi.  
 
MALDI Matrix Application 
Details of automated matrix application methods for lactate and glutamate analysis can be 
found in supplementary information. 
 
MALDI Quantative Mass Spectrometry Imaging (qMSI) 
MALDI-MSI experiments were carried out in negative reflectron mode over a mass range of 
m/z 60 to 1000 using a MALDI RapiFlex tissuetyper (lactate) or a UltrafleXtreme (glutamate) 
MALDI-TOF/TOF MS (Bruker Daltonics, Bremen, Germany) equipped with a 10kHz 
Smartbeam 3D
TM
 and a 2 kHz, smartbeam-II™ Nd:YAG laser respectively.  Data was 
collected on the RapiFlex was at a spatial resolution of 50 µm, summing up 500 laser 
shots/raster position. Data collection on the UltrafleXtreme was at a spatial resolution of 80 
µm, summing up 300 laser shots /raster position.  
FlexImaging 5.0 (Bruker Daltonics, Bremen, Germany) software was used for initial data 
analysis. Normalization, molecular image extraction and regions of interest for lactate 
quantitation were defined in SCiLS Lab 2017b (Supplier ?)  software typically using mass 
selection window of ± 0.05 Da. Glutamate quantitation was performed using msIQuant 
software
26
. Endogenous lactate, lactate 
13
C1 (for normalization) lactate 
13
C3 were detected at 
m/z 89.1, 90.1 and 92.1 respectively. 
  
Spectral Clustering Analysis 
Data were imported into Matlab (version R2017a and statistics toolbox, The Math-Works, 
Inc., Natick, MA, USA) using SpectralAnalysis version 1.01
27
. Briefly, a mean spectrum was 
generated for each dataset, which was peak picked using the SpectralAnalysis gradient peak 
picking. These peaks were then extracted into a datacube by integrating under the area for 
each peak. Data were then normalised to the 
13
C lactate or glutamate peak (nominally m/z 
90.028 and 147.048). These lactate and glutamate concentrations were then quantified to the 
calibration curves generated from spots applied to a separate tissue section. Clustering was 
then performed on each of the individual tissue sections using k-means clustering with k = 2-5 
(k = 4 shown), using the cosine distance metric
28
. Boxplots of lactate and glutamate 
concentration were generated using the Matlab function “boxplot” where the central line 
shows the median concentration, the box represents the 25-75% interquartile range of the data 
and the whiskers are one additional interquartile range above and below these. Any points 
outside this range are considered outliers marked by red crosses. 
 
Homogenization and Quantitation of Lactate Levels by LC-MS 
Details of the homogenization and LC-MS method can be found in the supplementary 
information. 
 
Results and Discussion 
Endogenous Amino Acid Stability Experiment 
 
Previous in-house experience of endogenous metabolite analysis using DESI-MSI had 
suggested that degradation of endogenous lactate within rat kidney tissue during sample 
preparation (data not reported) was possible. This ex-vivo change in endogenous small 
molecule levels was found to be related to the amount of time the tissues spent in the -20°C 
environment of the cryomicrotome during the sectioning process and appeared to stabilize 
during analysis when the sample is removed from the freezer and effectively kept in a 
desiccated nitrogen rich environment on the DESI stage. Prior to embarking on a quantitative 
study of lactate and glutamate concentrations in different tumor models it was thus necessary 
to establish a protocol to stabilize or make sure any degradation of the endogenous 
compounds within the tissues was as uniform as possible. Kidney sections were taken over a 
time course spanning 24h in total, the resulting sections were stored between time-points in 
one of three different conditions; (1) left in the cryostat thaw mounted at -16ºC, (2) thaw 
mounted, desiccated in N2, vacuum packed and stored at room temperature, or (3) thaw 
mounted, desiccated in N2, vacuum packed and stored at -80ºC. Sections from each time-point 
were analyzed in duplicate using DESI-MSI, a ‘fresh’ section was added to each slide 
immediately before analysis to give a baseline relative abundance of lactate (lac), aspartate 
(asp), glutamate (glu) or glutamine (glut) for comparison. DESI-MSI images and relative 
abundances derived from the analysis can be seen in figure 1. The images were spectrally 
segmented to separate the kidney cortex from the medullary region as the distribution of the 
amino acids was different in the two areas. As suspected, sections stored under conditions (1) 
exhibited a degradation of the signal corresponding to the four amino acids in the cortex over 
time. Lac, asp and glut response in the medulla of the kidney initially dropped but then 
remained stable at subsequent time-points. Asp levels trended in the opposite direction under 
the same conditions showing higher abundance in the medulla the longer the sections were 
stored. Sections stored under conditions (2) decreasing lac levels over the storage time in the 
renal cortex with a more stable response in the medulla over time. Glu and glut degradation in 
the cortex and medulla did stabilize under conditions (2), asp again showed a trend towards 
higher relative abundance over time in both tissue regions. Sections stored under conditions 
(3), indicated lac levels were more stable than those observed in (1) and (2) in both the cortex 
and medulla  giving a δ value of 3913 & 8740 respectively, versus  δ 28971 & 11691 in the 
cortex of kidneys stored in (1) and (2) and 42713 and 12094 in the medullary regions. Glu, 
Asp and glut levels were also found to be more stable under conditions (3) with 
corresponding improvements in δ values. These results highlighted the need for -80ºC storage, 
even over a short period of time. 
Interpreting the results further, it was clear that immediate desiccation post sectioning 
followed by vacuum packing and storage at -80ºC was needed to minimize the degradation of 
the endogenous metabolites in the tissue, however even with this safeguard, instability could 
still occur as multiple sections were cut one at a time onto the same microscope slide within 
the cryostat. To minimize the amount of time sections were kept in the cryostat chamber it 
was decided to embed multiple tissues in gelatin and section them all in a single cut of the 
microtome blade. This significantly reduces the amount of time the sections spend at 
temperatures higher than -20°C, with the added bonus of reduced sample preparation time. 
The embed, thaw mount, desiccate, vaccum pack and store at -80°C protocol was thus 
adopted for all subsequent analysis. 
 
Initial proof of principle 
In order to test the hypothesis that it was possible to quantify and map the spatial distribution 
of lactate in tumor tissue using qMSI, an initial study was performed in a NCI-H358 human 
xenograft mouse tumor model. Animals were treated with a proprietary drug (AZx) that is 
known to induce changes in tumor metabolism. Lactate distribution and concentration levels 
from tumors treated with AZx were compared to vehicle dosed control animals. Although 
DESI-MSI had been used in the initial stability experiments it was decided to proceed with a 
more validated quantitative imaging platform, MALDI-qMSI was thus used to map and 
quantify the lactate distribution within the tumor tissue. Due to the unavailability of a second 
stable-labelled version of lactate this analysis was performed with normalization to total ion 
current. The results from the analysis (Figure 2) showed that lactate changes could be 
observed in the tumor tissue after exposure with AZx. The analytical method performed well 
giving a linear response (R
2
 = 0.997) across the calibration range (Figure 2b), stable isotope-
labelled (
13
C3-lactate) calibration spots can be seen in blue in figure 2a. The dynamic range of 
the calibration line covered the lactate concentrations measured in the tumor tissue (170.0 – 
3525.6 µM). Lactate modulation was observed at 2 hours post dose (figure 2c, 100 mg/kg data 
shown as representative) which corresponded with the maximum concentration (Cmax) of 
orally administered AZx suggesting the pharmacodynamic response was linked to the 
pharmacokinetics of the drug. Lactate concentrations at 30 mins, 6 and 24 hrs were similar to 
those in the vehicle dosed animals. Mean intra-tumoral lactate levels in the control animals at 
each timepoint was 490.6 – 2464.0 µM giving a corresponding variation of 26.0 – 49.3% CV 
(n=4 animals at each timepoint) indicating a high level of variation between the vehicle dosed 
animals. Using the multiplex nature of MALDI-MSI it was possible to simultaneously map 
the distribution of glutamate (figure 2a) and the drug (data not shown) along with the lactate 
within the same tumors. Glutamate was distributed throughout the tumors, this was in stark 
contrast to lactate which was much more heterogeneously distributed and localized into the 
necrotic or pre-necrotic regions (identified using H&E staining) of the tissue. Glutamate 
levels in these lactate rich regions were much lower than those observed in the surrounding 
tissue giving a visual representation of the ‘Warburg effect’. 
 
Tumor model screening 
The heterogeneous lactate distribution in the NCI-H358 tumor model used in the initial study 
had been shown to lead to high inter-tumor variation in lactate levels. This could be due to 
several factors including the tumor model itself and the duration at which the tumors are 
allowed to mature. High inter-animal variation decreases the likelihood of detecting subtle 
differences in endogenous amino acid levels in the dosed animals compared to vehicle treated 
animals, this could be the reason that no lactate modulation was observed in the early and late 
timepoints of the initial study. A tumor model that exhibits a more homogeneous lactate 
distribution would be highly desirable and should reduce the inter-tumor variability giving a 
more robust model to move forward into efficacy testing and ultimately build a reliable 
PK/PD model. Several different tumor models were selected for lactate screening. An NCI-
H358 model, differentiated from the initial study by allowing the tumor to grow for less time 
and minimize the chance of necrosis, an MC38 model, a B16.F10.AP3 model and a MC38 
variant model were all screened using MALDI-MSI for both lactate and glutamate 
quantitation and distribution (adjacent sections). Models were analysed in different analytical 
batches (n=4 for each amino acid), the analytical method performed reliably throughout the 
analysis, calibration lines gave a consistent linear response (R
2
 = 0.9960 – 0.9978) with a 
gradient range of 0.0041 – 0.0098 and a intercept range of 0.0249 – 0.2649. Ion images are 
shown in Figure 3a. Tumors from the MC38 and B16.F10.AP3 models showed heterogeneous 
lactate distribution throughout the tumor tissue with little or no co-localization with 
glutamate. The MC38 tissue in particular had large areas of necrosis (confirmed by H&E), 
B16.F10.AP3 tumors were less necrotic but lactate and glutamate distribution was very 
localized and ‘patchy’ throughout the tissue. The NCI-H358 and MC38 variant tumors had 
more evenly distributed lactate and glutamate even in areas that were confirmed to be necrotic 
by H&E staining. 
Lactate and glutamate concentrations across each of the tissue sections were largely in the 
same range between the different models fluctuating between 81.7 – 2504.0 µM for lactate 
and 10955.0 – 78187.0 µM for glutamate. 
 
Regio-specific qMSI 
Spectral clustering was performed on each of the individual tissue sections from each model 
using k-means clustering with k = 2-5 (k = 4 shown), using the cosine distance metric. This 
analysis allowed regio-specific pixel by pixel quantitation of the lactate and glutamate levels 
to be calculated, this is represented graphically in the box plots in figure 4. From the boxplots 
of lactate and glutamate concentration in each region of each tissue, the lactate concentration 
was much more heterogeneous in the B15.F10 and MC38 models as seen by the large boxes, 
whiskers and many outliers. In comparison, the MC38 variant and NCI-H358 tumours have 
more homogeneously distributed lactate concentration (smaller boxes) with the MC38 variant 
displaying lower median inter-tumor lactate concentration variability. The glutamate 
concentration in all tissue models is overall less heterogeneous than the lactate concentration, 
with the different models containing similar levels of heterogeneity as seen by similar spreads 
of the data in the boxplots. 
The objective of the screening exercise was to identify a tumor model that had greater lactate 
homogeneity, lower lactate variability and fewer areas of necrosis. The MC38 variant model 
was selected as the analysis had shown this exhibited the most favorable properties of the four 
models tested. Subsequently, the MC38 variant model has allowed further efficacy studies to 
be performed. The more homogeneous lactate distribution and lower variability in the MC38 
variant model highlighted by the qMSI analysis has provided the confidence to analyze later 
studies using non-spatially resolved LC-MS with tissue homogenization. Initial data from the 
first study suggests that lactate levels within the control tumors measured by LC-MS resulted 
in a mean concentration of 473.4 µM ± 21.6% based on n=9 control tumors from the MC38 
variant model. Comparison of the vehicle dosed tumor lactate data with lactate data from 
tumors taken from animals dosed with an AZ project compound yielded statistically 
significant lactate modulation. The tumor model is now being effectively used to develop a 
PK/PD relationship to optimize efficacy in subsequent project compounds. 
 
Conclusion 
Early confirmation of drug efficacy in humans is of great value to drug discovery projects. 
Cellular or enzymatic assays can be used to determine compound potency but are rarely a 
substitute for in vivo experiments in syngeneic preclinical animal models. Determination of 
efficacy endpoints that are directly related to the target pathway in the form of endogenous 
metabolite differences in diseased human tissue is a gold standard. Thiscan however be 
misleading in complex tissue environments such as tumor tissue due to localization of the 
metabolites into different tissue compartments within the tumor.  
Here we have established sample pre-treatment protocols that minimize the degradation of 
endogenous amino acids within sectioned tissue, all tissues are handled in a standardized way 
and stored under the same conditions to ensure any degradation that does occur is uniform 
across all sections in the same experiment. 
We have demonstrated that the spatial resolution MSI can offer can be successfully used to 
assess the distribution of endogenous metabolites within different tumor models. We have 
also shown that MALDI-MSI can be used as a quantitative technique to measure the absolute 
concentration of these metabolites in situ, furthermore, we have shown how spectral 
clustering can be used to generate regio-specific concentration data within the tumor sections 
to give a more empirical illustration of tumor heterogeneity. 
Quantitative MSI methods such as those reported in this work can be expanded in the future. 
The multiplex nature of qMSI methods could allow simultaneous quantitation of several 
endogenous compounds in the same tissue section, it can also be used to encompase different 
endogenous compound classes such as lipids, peptides and proteins that can modulate with 
disease state and give evidence of target engagement or drug efficacy in many other potential 
therapeutic targets. 
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Figure 1: Stability of Lactate, aspartate, glutamate and glutamine in control kidney sections under 
different conditions. Bar charts show the relative abundance of the amino acids in the renal cortex and 
medulla under the different storage conditions over time. 
 
 
  
 Figure 2: a) Lactate and glutamate distribution in a NCI-H358 tumor model generated using 
quantitative mass spectrometry imaging. b) A calibration line used generated by spotting 
13
C3 stable 
labelled lactate onto control tissue. c) Graph showing the mean lactate concentration in tumors dosed 
wiith AZx and vehicle at different timepoints, differentiation between dosed and vehicle treated 
animals can be seen at the 2 hr timepoint. 
 
 
 
 Figure 3: Comparison of four mouse tumor models showing A) lactate (red) and glutamate (green) distribution generated by MALDI-qMSI, B) Clustering 
images of lactate in the different tumour model tissues and C) Clustering images of glutamate in the different tumour model tissues. The clustering images 
give a visual representation of the spectrally diverse regions within the tumor tissue. The colors of the different clusters correspond to the colors used in the 
box plots in figure 4. 
 
 
 
 Figure 4: Box plots showing pixel by pixel regio-specific lactate and glutamate concentration. Box 
colors correspond to the colors used in the clustering images in figure 3B & C.  
The boxplots show the differencing heterogeneity of the concentrations of lactate or glutamate based 
on the different tumour models. The MC38 variant and NCI-H358 tumours have more homogeneously 
distributed lactate concentration compared to the B15F10 and MC38 models, glutamate concentration 
is more homogeneous than lactate in all of the models. 
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